브리지바이오파마(주)
US ˙ NasdaqGS ˙ US10806X1028

SecurityBBIO / BridgeBio Pharma, Inc.
InstitutionFORA Capital, LLC
Latest Disclosed Ownership0 shares
Latest Disclosed Value $ 0
FORA Capital, LLC closes position in BBIO / BridgeBio Pharma, Inc.

On May 14, 2026 - FORA Capital, LLC filed a 13F-HR form disclosing ownership of 0 shares of BridgeBio Pharma, Inc. (US:BBIO) valued at $0 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 18,035 shares of BridgeBio Pharma, Inc.. The current value of the position is $0 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F BRIDGEBIO PHARMA COM 10806X102 0 -100.00 0
2026-02-13 2025-12-31 13F BRIDGEBIO PHARMA COM 10806X102 18,035 6,919 62.24 1,397 141.94 0.1689
2025-11-13 2025-09-30 13F BRIDGEBIO PHARMA COM 10806X102 11,116 -11,558 -50.97 577 -41.06 0.1020
2025-08-13 2025-06-30 13F BRIDGEBIO PHARMA COM 10806X102 22,674 -754 -3.22 979 21.01 0.1087
2025-05-14 2025-03-31 13F BRIDGEBIO PHARMA COM 10806X102 23,428 23,428 810 0.0821
2024-05-02 2024-03-31 13F BRIDGEBIO PHARMA COM 10806X102 0 -35,415 -100.00 0 -100.00
2024-02-14 2023-12-31 13F BRIDGEBIO PHARMA COM 10806X102 35,415 35,415 1,430 0.1228
2021-11-15 2021-09-30 13F BRIDGEBIO PHARMA, INC. CMN COM 10806X102 0 -2,033 -100.00 0 -100.00
2021-08-16 2021-06-30 13F BRIDGEBIO PHARMA, INC. CMN COM 10806X102 2,033 -301 -12.90 124 -13.89 0.0231
2021-05-17 2021-03-31 13F BRIDGEBIO PHARMA, INC. CMN COM 10806X102 2,334 -8,626 -78.70 144 -81.51 0.0473
2021-02-12 2020-12-31 13F BRIDGEBIO PHARMA, INC. CMN COM 10806X102 10,960 7,212 192.42 779 452.48 0.1189
2020-11-13 2020-09-30 13F BRIDGEBIO PHARMA, INC. CMN COM 10806X102 3,748 1,197 46.92 141 69.88 0.0924
2020-08-14 2020-06-30 13F BRIDGEBIO PHARMA, INC. CMN COM 10806X102 2,551 2,551 83 0.0284
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.